Mega Pharma

Active Private limited companyfounded 2011active for 15 yearsLeopold II laan 75, 1080 Molenbeek-Saint-JeanKBO/BCE: BE 0840.972.479

Mega Pharma

Follow Report Compare

Overview

Lifetime

14 annual accounts with figures on one time axis

Compare with

peak €164,640 (2024)

€130,361▼ 20.8%

lowest -€30,878 (2025)

-€30,878▼ €38,752

peak €183,451 (2022)

€131,985▼ 19.0%

€238,710▼ 7.0%

peak 1.2 FTE (2021)

-not published

Board1 name since 2021

1 director

Documentsfilings and deeds

29-07-20262 days before the deadline

2025micro format

Gross margin from €164,640 to €130,361Loss of €30,878Equity from €162,863 to €131,985Cash from €53,128 to €91,689

Key points

from the 2025 annual accounts

Staff

2 employees on 31-12-2025

In 2025, 1 person joined and 2 left.

Filings

14 annual accounts since 2012

The last five annual accounts were filed 2 to 55 days before the end of the period.

Position in the sector

-€30,878

Lower net result than 92% of companies in retail trade. Sector median €4,763 · 25,208 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 6,908 companies had the same profile as Mega Pharma has now. Each dot stands for 18 companies, two years later.

90.9%

were still trading

7.8%

stopped another way

1.1%

went bankrupt

Micro
10 to 20 years old
solvency 30% or more
a small loss

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group	Expected	Actual
1	0.2%	0.2%
2	0.3%	0.5%
3	0.5%	0.6%
4	0.7%	0.8%
5	0.9%	0.9%
6	1.3%	1.5%
7	1.6%	1.8%
8	1.8%	1.8%
9	2.9%	3.1%
10	5.6%	6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,908 companies, not a prediction for Mega Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director

Board & ownership

Recent changes

16-07-2026

Registered in the Peppol Directory Reachable for e-invoices through 0208:0840972479

11-01-2024

Change of role: , from manager to director Director discharge: · General meeting of 15-12-2023 · Gazette deed

19-12-2017

First establishment Leopold II laan 75, Molenbeek-Saint-Jean

10-11-2011

Incorporation published on 23-11-2011 · Gazette deed

All 25 events

Comparable companies

same main activity, similar in size and age

Company
Mega Pharma Molenbeek-Saint-Jean	€370,696	€130,361	35.6%	-
Pharmacie MORY Sint-Gillis (bij-Brussel)	€349,639	€131,549	28.9%	-
PHARMACIE DU MIROIR Jette	€358,930	€118,986	2.4%	-
PHARMACIE GILISQUET Schaerbeek	€391,819	€117,002	-80.8%	-
Pharmacie Marie-Anne TYCHON Liège	€362,681	€131,572	78.6%	-
Apotheek Werchter Rotselaar	€402,771	€129,592	52.3%	1
PHARMACIE DE BOUSSOIT La Louvière	€349,927	€119,641	65.4%	-

These companies have the same main activity as Mega Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €350,000 and €403,000, founded between 2010 and 2013.

Official details

Source: KBO

Status: Active since 10-11-2011Normal situation
Activity: Retail sale of pharmaceutical productsNACE 47730
Joint committee: 313Pharmacies and pricing offices · annual accounts 2024
Establishment unit: 2.270.810.1841080 Molenbeek-Saint-Jean, since 19-12-2017
Financial year end: 31 December
Peppol: Reachable since 16-07-2026

Company details

Annual accounts 2025

: €130,361▼ 20.8%
: ≈ €390,000estimated
: €30,878
: €131,985▼ 19.0%
: €370,696▼ 11.7%
Employeeson 31-12-2025: 2▼ 33.3%
Filing: Filed on 29-07-2026, 2 days before the end of the filing period

Financials

Insights on Mega Pharma

Mega Pharma files the micro format. That format states no turnover. The gross margin rose from -€1,146 in 2012 to €130,361 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

micro format, filed on 29-07-2026, 2 days before the deadline

€130,361

▼ 20.8%

-€20,935

▼ €58,324

-€30,878

▼ €38,752

€46,323

▲ 16.5%

35.6%

▼ 3.2 percentage points

1.22

▲ 0.04

The turnover shown is an estimate from the gross margin.

Turnover ≈ €390,000. Estimated: probably between €280,000 and €740,000.

Balance sheet

balance sheet total €370,696 on 31-12-2025

What the company ownsHow it is paid for

in euro

Position in the sector

Compare with sector

35.6%

Higher than 52% of 25,237 companies in 2025.

1.22

Higher than 41% of 24,245 companies in 2025.

-8.3%

Higher than 19% of 24,434 companies in 2025.

Mega Pharma Middle half of the sector 80% of the sector Micro accounts in retail trade (NACE 47)

Net result: bottom quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: middle half

Staff

€34,307

Staff costs divided by the average number of full-time equivalents.

-1 person

people who joined people who left

In 2025, 1 person joined and 2 left.

Filed annual accounts

as filed with the National Bank, click a year to choose it

Line	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Balance sheet: assets
`20/58`	370,696	419,628	525,516	462,366	511,229	524,069	541,640	552,610	15,707	14,909	13,838	13,221	12,521	12,730
`21/28`	112,953	163,508	214,063	191,850	231,407	270,964	304,920	342,920	-	-	-	-	-	-
`21`	66,000	99,000	132,000	165,000	198,000	231,000	264,000	297,000	-	-	-	-	-	-
`22/27`	46,033	63,588	81,143	25,930	32,487	39,044	40,000	45,000	-	-	-	-	-	-
`23`	10,624	15,872	21,119	25,930	32,487	39,044	40,000	45,000	-	-	-	-	-	-
`24`	35,409	47,716	60,023	-	-	-	-	-	-	-	-	-	-	-
`28`	920	920	920	920	920	920	920	920	-	-	-	-	-	-
`29/58`	257,743	256,120	311,454	270,517	279,822	253,104	236,721	209,690	15,707	14,909	13,838	13,221	12,521	12,730
`3`	38,676	64,981	64,975	62,448	54,650	68,068	60,982	59,780	-	-	-	-	-	-
`30/36`	38,676	64,981	64,975	62,448	54,650	68,068	60,982	59,780	-	-	-	-	-	-
`40/41`	125,774	138,011	178,646	187,637	183,979	161,381	91,818	56,221	15,693	14,881	13,776	13,125	12,417	12,622
`40`	56,774	57,343	48,255	48,724	51,461	43,415	59,052	51,221	-	-	-	-	-	-
`41`	69,000	80,668	130,391	138,913	132,518	117,966	32,766	5,000	15,693	14,881	13,776	13,125	12,417	12,622
`54/58`	91,689	53,128	67,636	20,232	39,750	22,739	82,115	93,421	14	28	62	96	105	108
`490/1`	1,602	0	197	199	1,442	916	1,806	268	-	-	-	-	-	-
Balance sheet: equity and liabilities
`10/49`	370,696	419,628	525,516	462,366	511,229	524,069	541,640	552,610	15,707	14,909	13,838	13,221	12,521	12,730
`10/15`	131,985	162,863	154,989	183,451	139,019	142,897	104,469	50,991	12,231	14,583	13,710	13,207	12,521	11,980
`10/11`	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400
`100`	-	-	-	-	-	-	18,600	18,600	18,600	18,600	18,600	18,600	18,600	18,600
`101`	-	-	-	-	-	-	6,200	6,200	6,200	6,200	6,200	6,200	6,200	6,200
`13`	119,585	150,463	142,589	38,591	38,591	38,591	38,591	38,591	344	344	300	200	100	-
`130/1`	-	-	0	591	591	591	-	-	-	-	-	-	-	-
`130`	-	-	-	-	-	-	1,860	1,860	344	344	300	200	100	-
`1311`	-	-	0	591	591	591	-	-	-	-	-	-	-	-
`133`	119,585	150,463	142,589	38,000	38,000	38,000	36,731	36,731	-	-	-	-	-	-
`14`	-	0	0	132,460	88,028	91,906	53,478	-	-513	1,839	1,010	607	21	-420
`17/49`	238,710	256,764	370,527	278,915	372,210	381,172	437,172	501,619	3,477	326	128	14	-	750
`17`	26,519	39,542	63,131	87,014	141,822	205,539	268,182	329,770	-	-	-	-	-	-
`170/4`	26,519	39,542	63,131	87,014	141,822	205,539	268,182	329,770	-	-	-	-	-	-
`42/48`	211,420	216,344	306,524	191,491	230,388	175,633	168,516	171,157	3,477	326	128	14	-	750
`42`	30,717	29,125	87,906	74,808	63,717	64,586	66,673	65,550	-	-	-	-	-	-
`43`	46,000	56,128	56,000	33,000	68,000	15,000	15,000	20,000	-	-	-	-	-	-
`430/8`	46,000	56,128	56,000	33,000	38,000	15,000	15,000	20,000	-	-	-	-	-	-
`439`	-	-	-	-	30,000	-	-	-	-	-	-	-	-	-
`44`	109,230	103,897	98,665	62,396	72,172	77,100	71,991	68,035	3,477	-	-	-	-	750
`440/4`	109,230	103,897	98,665	62,396	72,172	77,100	71,991	68,035	3,477	-	-	-	-	750
`45`	25,473	27,194	25,954	21,287	26,499	18,948	14,851	3,607	-	326	128	14	-	-
`450/3`	8,905	14,537	12,580	13,404	18,176	12,871	10,694	3,607	-	326	128	14	-	-
`454/9`	16,567	12,657	13,374	7,883	8,324	6,076	4,157	-	-	-	-	-	-	-
`47/48`	-	0	38,000	-	-	-	0	13,964	-	-	-	-	-	-
`492/3`	771	878	872	410	-	0	474	692	-	-	-	-	-	-
Income statement
`9900`	130,361	164,640	126,325	159,696	113,553	116,525	133,313	103,536	-51	-156	-263	-154	-310	-1,146
`62`	99,490	73,201	64,909	47,179	72,604	24,884	15,508	-	-	-	-	-	-	-
`630`	50,555	50,555	40,561	39,557	39,557	38,628	38,000	38,000	-	-	-	-	-	-
`640/8`	1,252	3,496	1,095	1,188	4,027	2,305	1,930	1,898	3,477	-	-	3	-	-
`9901`	-20,935	37,389	19,760	71,773	-2,635	50,708	77,875	63,638	-3,528	-156	-263	-156	-310	-1,146
`75/76B`	4,001	6,043	7,136	8,598	7,417	6,834	653	74	1,286	1,260	914	864	858	734
`75`	4,001	6,043	7,136	8,598	7,417	6,834	653	74	1,286	1,260	914	864	858	734
`65/66B`	13,944	27,587	11,768	22,831	8,162	9,124	10,186	9,952	34	34	34	9	7	8
`65`	13,944	27,587	11,768	22,831	8,162	9,124	10,186	9,952	34	34	34	9	7	8
`9903`	-30,878	15,845	15,129	57,539	-3,379	48,419	68,342	53,760	-2,276	1,071	618	699	541	-420
`67/77`	0	7,970	5,591	13,107	499	9,990	14,864	15,000	76	198	114	14	0	-
`9904`	-30,878	7,874	9,538	44,432	-3,878	38,428	53,478	38,760	-2,352	873	503	685	541	-420
`9905`	-30,878	7,874	9,538	44,432	-3,878	38,428	53,478	38,760	-2,352	873	503	685	541	-420
Appropriation of the result
`9906`	-30,878	7,874	141,998	132,460	88,028	91,906	53,478	38,247	-513	1,883	1,110	707	121	-420
`14P`	-	0	132,460	88,028	91,906	-	-	-	-	-	-	-	-	-
`791/2`	30,878	0	38,000	-	-	-	-	-	-	-	-	-	-	-
`691/2`	0	7,874	141,998	-	-	-	0	38,247	-	44	100	100	100	-
`6920`	-	-	-	-	-	-	0	1,516	-	44	100	100	100	-
`6921`	0	7,874	141,998	-	-	-	0	36,731	-	-	-	-	-	-
`694/7`	-	0	38,000	-	-	-	-	-	-	-	-	-	-	-
`694`	-	0	38,000	-	-	-	-	-	-	-	-	-	-	-
Social balance sheet
`9087`	2.9	2.3	1	0.8	1.2	0.5	0.5	-	-	-	-	-	-	-
Hours worked`1013`	3,213	2,028	1,814	1,427	2,053	783	798	-	-	-	-	-	-	-
Document	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF

The notes to these accounts have 15 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 29-07-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank

Financial year	Type	Filed	Reference	Document
31-12-2025	micro format	29-07-2026	2026-00360143	PDF
31-12-2024	micro format	17-06-2025	2025-00145875	PDF
31-12-2023	full format	06-06-2024	2024-00119715	PDF
31-12-2022	full format	10-07-2023	2023-00243050	PDF
31-12-2021	full format	15-07-2022	2022-20190664	PDF
31-12-2020	micro format	12-07-2021	2021-34900037	PDF
31-12-2019	micro format	28-05-2020	2020-13500249	PDF
31-12-2018	micro format	24-06-2019	2019-21400318	PDF
31-12-2017	micro format	21-06-2018	2018-21300221	PDF
31-12-2016	micro format	31-07-2017	2017-39900178	PDF
31-12-2015	full format	29-08-2016	2016-54000143	PDF
31-12-2014	full format	24-08-2015	2015-50900454	PDF
31-12-2013	full format	17-07-2014	2014-33400127	PDF
31-12-2012	full format	29-07-2013	2013-38400507	PDF

Key figures and ratios

per financial year, computed from the annual accounts

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
29,620	87,944	60,321	111,330	36,922	89,336	115,875	101,638	-	-	-	-	-	-
19,677	58,429	50,099	83,989	35,679	77,056	91,478	76,761	-	-	-	-	-	-
0	0	62,774	0	0	4,672	0	380,920	-	-	-	-	-	-
38,561	-14,508	47,403	-19,518	17,011	-59,375	-11,306	93,407	-14	-34	-34	-9	-3	-
46,323	39,776	4,929	79,025	49,434	77,471	68,205	38,533	12,231	14,583	13,710	13,207	-	11,980
35.6%	38.8%	29.5%	39.7%	27.2%	27.3%	19.3%	9.2%	77.9%	97.8%	99.1%	99.9%	100.0%	94.1%
1.22	1.18	1.02	1.41	1.21	1.44	1.40	1.23	4.52	45.75	-	-	-	16.97
1.04	0.88	0.80	1.09	0.98	1.05	1.04	0.88	4.52	45.75	-	-	-	16.97
1.81	1.58	2.39	1.52	2.68	2.67	4.18	9.84	0.28	0.02	0.01	0.00	-	0.06
-23.4%	4.8%	6.2%	24.2%	-2.8%	26.9%	51.2%	76.0%	-19.2%	6.0%	3.7%	5.2%	4.3%	-3.5%
-8.3%	1.9%	1.8%	9.6%	-0.8%	7.3%	9.9%	7.0%	-15.0%	5.9%	3.6%	5.2%	4.3%	-3.3%
2.12	3.19	5.13	4.88	4.52	-	-	-	-	-	-	-	-	-

EBIT margin: not included in this filing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item	31-12-2025	31-12-2024	31-12-2023	31-12-2022	31-12-2021
Employees at the balance-sheet date	2	3	2	2	1
full-time	0	0	0	0	0
part-time	2	3	2	2	1
in full-time equivalents	1.3	1.6	1	1	0.5
	1.8	1.2	1	0.8	1.2
On a permanent contract	2	2	2	2	1
Joined	1	1	-	3	1
Left	2	0	-	2	1

Source: social balance sheet in the 2021 to 2025 annual accounts

Securities and guarantees

on own assets and for others

Item	2025	2024	2023	2022	2021
Debts secured on the company's own assets	-	-	€141,037	€141,822	€205,539
	-	-	-	€250,000	€250,000
	€490,000	€490,000	€490,000	€490,000	€490,000

Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)

Investments

fixed assets acquired

Item	2025	2024	2023	2022	2021
Tangible fixed assets	-	-	€62,774	-	-
Financial fixed assets	€0	-	-	-	-
	€50,555	€50,555	€40,561	€39,557	€39,557

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on Mega Pharma

The operating result for 2025 is a loss of €20,935, after a profit of €37,389 in 2024. It is the lowest result since 2012.

Debt's share of the balance-sheet total rises from 61.2% to 64.4%. Equity and debt are lower.

Board & ownership

Board

1 director, last change in 2024

Director (not named in the articles)

appointed by deed of 11-01-2024

earlier manager, until 11-01-2024

listed in the 2024 annual accounts, filed on 17-06-2025

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today

Director (not named in the articles)

BoardEarliermandate already running before its first mention

Mandates as a list

- Director (not named in the articles), since before 31-12-2021
- Manager, until 11-01-2024

See the board, name and registered office on a given date →

Control

See the annual accounts at the National Bank and the publications in the Belgian Official Gazette.

Capital

Contribution: €12,400
Source: 2025 annual accounts

Articles of association

deed of 11-01-2024 (in French)

Duration: Unlimited
Transfer restriction: “Moitié cédant moitié acquéreurs au prorata si plusieurs, Article 9”
Annual meeting: Last Wednesday of May at 19:00

Network & group

No group

Mega Pharma has no parent and no holdings in its annual accounts. is the only director. Mega Pharma shares no director with another company.

At the same address

Leopold II laan 75, 1080 Molenbeek-Saint-Jean · 2 other companies

Association des copropriétaires de l'immeuble sis à Mol-St-Jean, bvd. Léopold II 75. registered office since 12-04-2001	founded in 2001 0823.954.820
Van Meensel, Arlette (sole trader) establishment since 05-09-1995	founded in 1973 0553.160.217

Timeline

25 events since 2011

Board

Filings

Financial

Establishments

20122014201620182020202220242026

Deadline for the 2026 accounts: 31-07-2027

2026

29-07-2026

Annual accounts 2025 filed NBBmicro format · 2 days before the deadline

16-07-2026

Registered in the Peppol Directory Reachable for e-invoices through 0208:0840972479

2025

31-12-2025

Weakest financial year net -€30,878 The net result drops to -€30,878, the lowest from 2012 to 2025.

17-06-2025

Annual accounts 2024 filed PDFmicro format · 44 days before the deadline

2024

06-06-2024

Annual accounts 2023 filed PDFfull format · 55 days before the deadline

11-01-2024

Change of role: , from manager to directorDirector discharge: · General meeting of 15-12-20236 points ▸

General meeting, 15-12-2023
186 shares
Director resignation, (manager)
Director appointment, (director (not named in the articles))
Director discharge,
Registered office clause, Boulevard Léopold II 75
The deed holds 2 more points.

Open the deed in the Belgian Official Gazette

2023

10-07-2023

Annual accounts 2022 filed PDFfull format · 21 days before the deadline

2022

31-12-2022

Back to profit net €44,432 The net result is €44,432, after one loss-making year.

31-12-2022

Equity above €150,000 equity €183,451 ▲32% Equity rises from €139,019 to €183,451.

15-07-2022

Annual accounts 2021 filed PDFfull format · 16 days before the deadline

2021

12-07-2021

Annual accounts 2020 filed PDFmicro format · 19 days before the deadline

2020

28-05-2020

Annual accounts 2019 filed PDFmicro format · 64 days before the deadline

2019

31-12-2019

Highest result from 2012 to 2025 net €53,478 ▲38% The operating result of €77,875 and the net result of €53,478 are both a record.

31-12-2019

Equity above €100,000 equity €104,469 ▲105% After 2 profitable years in a row, equity reaches €104,469.

24-06-2019

Annual accounts 2018 filed PDFmicro format · 37 days before the deadline

2018

31-12-2018

Back to profit net €38,760 The net result is €38,760, after one loss-making year.

21-06-2018

Annual accounts 2017 filed PDFmicro format · 40 days before the deadline

2017

19-12-2017

First establishment Leopold II laan 75, Molenbeek-Saint-Jean

31-07-2017

Annual accounts 2016 filed PDFmicro format · on the deadline day

2016

29-08-2016

Annual accounts 2015 filed PDFfull format · 29 days late

2015

24-08-2015

Annual accounts 2014 filed PDFfull format · 24 days late

2014

17-07-2014

Annual accounts 2013 filed PDFfull format · 14 days before the deadline

2013

31-12-2013

Back to profit net €541 The net result is €541, after one loss-making year.

29-07-2013

Annual accounts 2012 filed PDFfull format · 2 days before the deadline

2011

10-11-2011

Incorporation PDFpublished on 23-11-2011

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official Gazette Filings with the National Bank

History

On 10 November 2011, Mega Pharma was incorporated.¹ Total assets went from €552,610 in 2018 to €370,696 in 2025 and headcount from 0.5 full-time equivalents in 2019 to 2.9 in 2025.²

Company details

Identity

Enterprise number: 0840.972.479
VAT number: BE 0840.972.479
Peppol ID: 0208:0840972479
Other Peppol ID: 9925:BE0840972479
Legal form: Private limited company
Status: Active, normal situation
Founded: 10-11-2011
Financial year: ends on 31 December
Annual meeting: Last Wednesday of May at 19:00
deed of 11-01-2024 (in French)
Peppol: Reachable since 16-07-2026Follow this company and you will hear the next morning if it leaves the Peppol register.
Name: Mega Pharma in French
Entity type: Legal entity
Duration: Unlimited
deed of 11-01-2024 (in French)
Name clause: Mega Pharma
deed of 11-01-2024 (in French)
Registered office clause: “Région de Bruxelles Capitale”
deed of 11-01-2024 (in French)

Activities

NACEBEL 2025

VAT activities

47730 Retail sale of pharmaceutical products main activity

Social security (RSZ) activities

47730 Retail sale of pharmaceutical products main activity

Joint committees annual accounts 2024

JC 313 Pharmacies and pricing offices

Codes under NACEBEL 2008

VAT activities

47730 Retail trade main activity

Social security (RSZ) activities

47730 Retail trade main activity

Purpose: “Toutes opérations généralement quelconques,industrielles,commerciales,financières,mobilières ou immobilières se rapportant directement aux…”
5 activities
Toutes opérations généralement quelconques,industrielles,commerciales,financières,mobilières ou immobilières se rapportant directement aux activités d'exploitation d'officines pharmaceutiques,homéopathiques et de bandagisteries,ainsi que la fabrication et la commercialisation de produits pharmaceutiques,homéopathiques et cosmétologiques.
La constitution et la valorisation d'un patrimoine immobilier.
Toutes opérations généralement quelconques se rapportant directement ou indirectement à son objet social ou susceptibles de favoriser son développement.
Prendre la direction et le contrôle,en sa qualité d'administrateur,liquidateur ou autrement de sociétés affiliées ou filiales,et leur prodiguer des avis.
Par voie d'apport en espèce ou en nature,de fusion,de souscription,de participation,d'intervention financière ou autrement,prendre des participations dans d'autres sociétés ou entreprises existantes ou à créer,que ce soit en Belgique ou à l'étranger,dont l'objet social serait semblable ou analogue au sien ou de nature à favoriser son objet social.
deed of 11-01-2024 (in French)

Registered office and establishments

1 establishment

Establishment	Since	Unit number	FASFC approval
Leopold II laan 75 registered office 1080 Molenbeek-Saint-Jean	19-12-2017	2.270.810.184	Pharmacy (food >3 months)

Buildings and parcels at the address

Ground area: 130 m²
Buildings: 135 m²
Volume, LiDAR: 1,460 m³
Tallest building: 19.4 m

Buildings to scale, each on its own parcel

registered office establishment The establishment unit on the map

3 companies at this address See who is registered here

Parcels

Cadastral parcel	Area	Buildings	Height / floors
21012A0182/00S000	130 m²	1 · 135 m²	19.4 m · 4

Recognitions

Food safety, FASFC

1 site

Molenbeek-Saint-Jeanunit number 2.270.810.184

1 permission

Pharmacy (food >3 months) · since 19-12-2017

Source: FAVV-AFSCA, open data, updated on 02-11-2026

Overview

Lifetime

Key points

Staff

Filings

Position in the sector

Checked score

Score breakdown

Comparable companies, two years later

Credit verdict

Signals

Board and ownership

Recent changes

Comparable companies

Official details

Annual accounts 2025

Insights on Mega Pharma

Financials

Annual accounts 2025

Balance sheet

Change in equityin euro

Change in cashin euro

Position in the sector

Solvency35.6%

Current ratio1.22

Return on assets-8.3%

Staff

Staff cost per FTE€34,307

Joined and left-1 person

Filed annual accounts

Filings

Key figures and ratios

Social balance sheet

Securities and guarantees

Investments

Insights on Mega Pharma

Board & ownership

Board

Mandates through the years

Control

Capital

Articles of association

Network & group

No group

At the same address

Timeline

Timeline

History

Company details

Identity

Activities

Registered office and establishments

Buildings and parcels at the address

Location

Parcels

Recognitions

Food safety, FASFC

in euro

in euro

35.6%

1.22

-8.3%

€34,307

-1 person